greeksoup/ stock research

Elevance Health (ELV) Q3 FY2022 earnings: revenue $39.9 billion, up 11.5% on the year

Elevance Health, Inc. (ELV) reported revenue of $39.9 billion for Q3 FY2022, the quarter ended 30 September 2022, up 11.5% on the same quarter a year earlier as this quarter's filing gives it. Net income was $1.6 billion, up 6.2% on the year, and diluted earnings per share $6.62. The figures are the company's own, from the 10-Q it filed with the SEC on 19 October 2022.

Revenue
$39.9 billion
+11.5% on the year · +3.4% on the quarter
Q4 FY2020Q3 FY2022
Operating margin
5.6%
5.7% a year earlier
Q4 FY2020Q3 FY2022
Net income
$1.6 billion
+6.2% on the year · -2.1% on the quarter
Q4 FY2020Q3 FY2022
Diluted EPS
$6.62
+8.0% on the year · -1.6% on the quarter
Q4 FY2020Q3 FY2022

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ3 FY2022Q2 FY2022Q3 FY2021On the quarterOn the yearLast 8 quarters
Revenue39,93938,63235,822+3.4%+11.5%
Cost of revenue3,4373,069n/a+12.0%
Gross profit36,50235,563n/a+2.6%
Gross margin91.4%92.1%n/a
Selling, general and administrative4,5144,269n/a+5.7%
Operating income2,2512,3462,059-4.0%+9.3%
Operating margin5.6%6.1%5.7%
Interest expense213208n/a+2.4%
Pre-tax income2,1272,122n/a+0.2%
Income tax529488n/a+8.4%
Effective tax rate24.9%23.0%n/a
Net income1,6031,6371,509-2.1%+6.2%
Net margin4.0%4.2%n/a
Diluted EPS$6.62$6.73$6.13-1.6%+8.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ3 FY2022Q2 FY2022Q3 FY2021On the quarterOn the yearLast 8 quarters
Operating cash flow4,9242,452n/a+100.8%
Capital expenditure305295n/a+3.4%
Free cash flow4,6192,157n/a+114.1%
Free cash flow margin11.6%5.6%n/a
Cash from investing-1,247-2,024n/a
Cash from financing-1,255-127n/a
Depreciation and amortisation451393351+14.8%+28.5%
Share-based compensation69.072.0n/a-4.2%
Buybacks579624n/a-7.2%
Dividends paid306309n/a-1.0%
Dividend per share$1.28$1.28n/a0.0%
Diluted shares, weighted242m243m246m-0.5%-1.5%
Shares outstanding at period end239m240m243m-0.4%-1.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2022Q2 FY2022Q3 FY2021On the quarterOn the yearLast 8 quarters
Shareholders' equity35,99135,81235,737+0.5%+0.7%
Non-controlling interest52.055.0n/a-5.5%
Debt23,77223,58822,785+0.8%+4.3%
Operating lease liabilities739n/an/a
Other liabilities42,47241,422n/a+2.5%
Total liabilities and equity103,026100,877n/a+2.1%
Fixed assets4,1974,090n/a+2.6%
Goodwill24,38124,367n/a+0.1%
Intangible assets10,53610,762n/a-2.1%
Investments26,14826,368n/a-0.8%
Cash and equivalents8,8726,4565,490+37.4%+61.6%
Other assets28,89228,834n/a+0.2%
Total assets103,026100,877n/a+2.1%

Questions

What was Elevance Health's revenue in Q3 FY2022?

Elevance Health (ELV) reported revenue of $39.9 billion for Q3 FY2022, the quarter ended 30 September 2022, up 11.5% on the same quarter a year earlier as the company restated it.

How much did Elevance Health earn in Q3 FY2022?

Net income for Q3 FY2022 was $1.6 billion, up 6.2% on the year, and diluted earnings per share $6.62.

When did Elevance Health report Q3 FY2022 results?

Elevance Health filed its 10-Q for the quarter ended 30 September 2022 with the SEC on 19 October 2022.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022 †Q2 FY2022 †Q3 FY2022 †Q4 FY2022 * †Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024 †Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue36,58138,09538,63239,93939,92942,17243,67242,84942,64742,57743,88645,10645,44248,89149,77650,71149,74750,18150,47451,429
Cost of revenue3,0702,8833,0693,4373,6463,4814,3274,6484,8373,8254,8205,0936,0124,9835,2935,3805,5225,4635,4925,640
Gross profit33,51135,21235,56336,50236,28338,69139,34538,20137,81038,75239,06640,01339,43043,90844,48345,33144,22544,71844,98245,789
Gross margin92%92%92%91%91%92%90%89%89%91%89%89%87%90%89%89%89%89%89%89%
SG&A4,2224,3414,2694,5144,5624,8004,8185,4704,9994,8865,0665,2694,8045,3004,9975,2725,4156,3305,5475,752
Operating income1,1882,4272,3462,2511,2592,8312,6281,7561,2843,0162,7651,4086733,1702,4251,2953092,0861,7631,269
Operating margin3%6%6%6%3%7%6%4%3%7%6%3%1%6%5%3%1%4%3%2%
Interest expense200201208213229251261259259265280300340344341351366357364358
Pre-tax income1,4002,3062,1222,1271,0452,6192,4411,6541,0012,9392,9861,3736062,7972,2921,4062152,3041,9371,794
Tax rate20%23%23%25%16%23%24%21%17%23%23%27%32%22%24%16%-154%24%25%25%
Net income1,1371,7891,6371,6038651,9891,8531,2898562,2462,3001,0164182,1831,7431,1895471,7641,4631,365
Net margin3%5%4%4%2%5%4%3%2%5%5%2%1%4%4%2%1%4%3%3%
Diluted EPS$4.64$7.32$6.73$6.62$3.95$8.30$7.79$5.45$3.63$9.59$9.85$4.36$1.81$9.61$7.72$5.32$2.47$8.00$6.71$6.27
Operating cash flow1,6722,5412,4524,924-1,5186,4691,9502,613-2,9711,9784472,6777061,0172,0541,13584.04,3321,9131,267
Capital expenditure340254295305298301350319326279323332322196267360293235287267
Free cash flow1,3322,2872,1574,619-1,8166,1681,6002,294-3,2971,6991242,3453848211,787775-2094,0971,6261,000
Buybacks52254562457956862264648092856646360.01,8118803788764711,124234330
Dividends paid273309309306305351350348346379378386373386385381377376373373
Shares outstanding242m241m240m239m238m237m236m235m233m233m232m232m227m226m225m222m221m217m217m216m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2022, filed 19 October 2022: the filing.